Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2020

View Archived Issues

Reservoir dogs don't hunt

Different drivers can turn the wheel in glioblastoma's vicious cycle

Phase II/III DISTINCT study of Unituxin does not meet primary endpoint

Positive top-line results from phase II WILLOW study of INS-1007

Successful completion of U.S. phase I study of liposomal annamycin in AML

HVTN702 HIV vaccine study stopped early due to non-efficacy

Safety and early signs of clinical efficacy for SBP-101 plus gemcitabine and nab-paclitaxel in PDA

First-in-human data presented for AbGn-107

9-ING-41 shows promising preliminary safety and efficacy in gastrointestinal cancers

Initial first-in-human data presented for OTL-102

Nr4a1 regulates gene transcription during cocaine abstinence: a potential target against addiction

Gedeon Richter patents nicotinic acetylcholine alpha7 receptor PAMs

Verseon divulges new thrombin inhibitors

Gilead Sciences presents PD-1/PD-L1 inhibitors

Efficacy seen in phase II study of cabozantinib in refractory metastatic colorectal cancer

Anacor Pharmaceuticals synthesizes compounds for trypanosomiasis

Jiangsu Chia Tai Tianqing Pharmaceutical Group synthesizes BTK inhibitors

Nanoparticle monotherapy effective in HER2+ breast cancer in mice

FDA issues complete response letter for Luye's LY-03004 for schizophrenia and bipolar I disorder

Gerbil model of cholesteatoma developed to test oncolytic HSV potential

Active molecular changes in the BBB associated with stress resilience may protect against depression

B4GALNT1 and its products GM2/GD2 enhance tumorigenesis in melanoma by inducing angiogenesis

Aurigene initiates phase II study of AUR-101 in moderate to severe psoriasis

SBIR grant supports Plex's development of antivirals for dengue, West Nile virus and Zika

FDA approves Audenz to protect against influenza A (H5N1)

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema
BioWorld
Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...